Last reviewed · How we verify
Tpo-RA discontinuation
Tpo-RA discontinuation refers to the cessation of thrombopoietin receptor agonist therapy, allowing platelet counts to normalize after treatment withdrawal.
Tpo-RA discontinuation refers to the cessation of thrombopoietin receptor agonist therapy, allowing platelet counts to normalize after treatment withdrawal. Used for Management strategy for patients previously treated with thrombopoietin receptor agonists for immune thrombocytopenia.
At a glance
| Generic name | Tpo-RA discontinuation |
|---|---|
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
Mechanism of action
Thrombopoietin receptor agonists (Tpo-RAs) such as romiplostim and eltrombopag stimulate megakaryopoiesis and platelet production by activating the thrombopoietin receptor. Discontinuation of these agents results in a gradual decline in platelet production as the pharmacological stimulus is removed, returning patients to their baseline platelet-generating capacity. This is a management strategy rather than a therapeutic agent itself.
Approved indications
- Management strategy for patients previously treated with thrombopoietin receptor agonists for immune thrombocytopenia
Common side effects
- Thrombocytopenia (platelet count decline)
- Bleeding risk
Key clinical trials
- The Combination of ATRA and Eltrombopag as the Treatment of Steroid-resistant/Relapse ITP Based on MSC-C5b-9 (PHASE3)
- Rate of Prolonged Response After Stopping Thrombopoietin-receptor Agonists Treatment in ITP (PHASE4)
- TPO-RA Treatment on Immune Tolerance Induction of ITP Patients With Sustained Platelet Recovery After Treatment Termination (PHASE2)
- A Clinical Study of Herombopag in Tumors-associated Thrombocytopenia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tpo-RA discontinuation CI brief — competitive landscape report
- Tpo-RA discontinuation updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI